» Articles » PMID: 36992866

Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center

Overview
Date 2023 Mar 30
PMID 36992866
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: New therapeutic approaches for ulcerative colitis (UC) are now available, but there is still no robust evidence for predictors of poor outcomes. We aimed to evaluate the factors associated with a chronic active UC disease course.

Patients And Methods: Data of all UC outpatients followed for at least 3 years after diagnosis between 2005 and 2018 were retrospectively collected. The primary aim was to identify risk factors for chronic active disease 3 years after diagnosis. Moreover, the following variables were investigated: proximal disease extension or disease regression, proctocolectomy, early use of biologics (BIO) or immunomodulators (IMM), hospitalization, colorectal cancer, and adherence. We defined adherence as both, taking the prescribed therapy and constancy in scheduled follow-up visits.

Results: A total of 345 UC patients followed for a median period of 82 months were included. Patients with extensive colitis at diagnosis had a higher rate of chronic active disease 3 years after diagnosis (p<0.012) together with a higher rate of surgery (p<0.001) at maximum follow-up. Patients with pancolitis showed significant disease regression over time (51%) without differences in treatment. The only factor associated with chronic active disease was non-adherence (p < 0.03; OR 0.49, 95% CI: 0.26-0.95). Adherent patients developed chronic active disease (p<0.025) less frequently but did receive more frequent IMM (p<0.045) or BIO (p<0.009) therapy.

Conclusion: Patients diagnosed with pancolitis were more likely to have chronic active disease and to undergo colectomy. The only predictor for developing chronically active UC regardless of disease extension was the lack of adherence to therapy within the first 3 years after diagnosis, underlining the importance of tight control of UC patients and the need to timely identify potential risk factors for non-adherence.

Citing Articles

Psychological impairment in inflammatory bowel diseases: the key role of coping and defense mechanisms.

Martino G, Viola A, Vicario C, Bellone F, Silvestro O, Squadrito G Res Psychother. 2024; 26(3).

PMID: 38224215 PMC: 10849073. DOI: 10.4081/ripppo.2023.731.


Impact of an intervention program on drug adherence in patients with ulcerative colitis: Randomized clinical trial.

Pacheco M, Sa P, Santos G, Boa-Sorte N, Domingues K, Assis L PLoS One. 2023; 18(12):e0295832.

PMID: 38150452 PMC: 10752503. DOI: 10.1371/journal.pone.0295832.

References
1.
Satsangi J, Silverberg M, Vermeire S, Colombel J . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55(6):749-53. PMC: 1856208. DOI: 10.1136/gut.2005.082909. View

2.
Siegel C, Whitman C, Spiegel B, Feagan B, Sands B, Loftus Jr E . Development of an index to define overall disease severity in IBD. Gut. 2016; 67(2):244-254. DOI: 10.1136/gutjnl-2016-312648. View

3.
Al Khoury A, Xiao Y, Golovics P, Kohen R, Afif W, Wild G . Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort. Dig Liver Dis. 2021; 53(8):980-986. DOI: 10.1016/j.dld.2021.02.006. View

4.
Qiu Y, Chen B, Li Y, Xiong S, Zhang S, He Y . Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study. BMC Gastroenterol. 2019; 19(1):7. PMC: 6327558. DOI: 10.1186/s12876-018-0928-2. View

5.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View